1. Home
  2. RMBS vs ABVX Comparison

RMBS vs ABVX Comparison

Compare RMBS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rambus Inc.

RMBS

Rambus Inc.

HOLD

Current Price

$114.28

Market Cap

10.2B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$120.70

Market Cap

9.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMBS
ABVX
Founded
1990
2013
Country
United States
France
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
9.2B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
RMBS
ABVX
Price
$114.28
$120.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
11
Target Price
$102.00
$130.09
AVG Volume (30 Days)
1.9M
1.8M
Earning Date
02-02-2026
08-11-2025
Dividend Yield
N/A
N/A
EPS Growth
30.64
N/A
EPS
2.10
N/A
Revenue
$678,488,000.00
$6,231,374.00
Revenue This Year
$29.03
$6.80
Revenue Next Year
$16.19
N/A
P/E Ratio
$54.88
N/A
Revenue Growth
31.05
N/A
52 Week Low
$40.12
$4.77
52 Week High
$135.75
$148.83

Technical Indicators

Market Signals
Indicator
RMBS
ABVX
Relative Strength Index (RSI) 61.41 48.89
Support Level $88.50 $113.64
Resistance Level $135.75 $125.86
Average True Range (ATR) 6.43 7.91
MACD 2.40 -0.48
Stochastic Oscillator 54.73 56.80

Price Performance

Historical Comparison
RMBS
ABVX

About RMBS Rambus Inc.

Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: